切换至 "中华医学电子期刊资源库"

中华实验和临床感染病杂志(电子版) ›› 2019, Vol. 13 ›› Issue (02) : 167 -171. doi: 10.3877/cma.j.issn.1674-1358.2019.02.015

所属专题: 文献

论著

乳腺癌患者高危型人乳头状瘤病毒感染、p53蛋白表达及淋巴结转移分析
郭静姝1,(), 陈群1   
  1. 1. 710000 西安市,西北妇女儿童医院乳腺科
  • 收稿日期:2018-09-25 出版日期:2019-04-15
  • 通信作者: 郭静姝

Analysis on high-risk human papillomavirus infection, p53 protein expression and lymph node metastasis of patients with breast cancer

Jingshu Guo1,(), Qun Chen1   

  1. 1. Department of Breastology, Northwest Women and Children Hospital, Xi’an 710000, China
  • Received:2018-09-25 Published:2019-04-15
  • Corresponding author: Jingshu Guo
  • About author:
    Corresponding author: Guo Jingshu, Email:
引用本文:

郭静姝, 陈群. 乳腺癌患者高危型人乳头状瘤病毒感染、p53蛋白表达及淋巴结转移分析[J/OL]. 中华实验和临床感染病杂志(电子版), 2019, 13(02): 167-171.

Jingshu Guo, Qun Chen. Analysis on high-risk human papillomavirus infection, p53 protein expression and lymph node metastasis of patients with breast cancer[J/OL]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2019, 13(02): 167-171.

目的

分析乳腺癌患者高危型人乳头状瘤病毒(HPV)感染、p53蛋白表达和淋巴结转移率。

方法

选取2016年5月至2018年5月于西北妇女儿童医院治疗的乳腺癌患者共90例作为观察组,选取同期于本院治疗乳腺增生患者90例作为对照组。对癌组织行HPV基因分型和p53蛋白检测,增生组织行HPV基因分型。观察入组患者高危型HPV感染率,分析乳腺癌患者肿瘤大小、TNM分期、淋巴结转移率与p53蛋白表达等。

结果

观察组患者中共60例发生高危型HPV感染,对照组中共36例发生高危型HPV感染,观察组患者中HPV16、18基因型感染率分别为21.11%(19/90)和22.22%(20/90),均高于对照组[2.22%(2/90)和2.22%(2/90)],差异均有统计学意义(χ2 = 7.108、P = 0.001,χ2 = 8.063、P = 0.001)。观察组HPV阳性患者淋巴结转移率为93.33%(56/60),显著高于HPV阴性患者(21/30、70.00%),差异有统计学意义(χ2 = 4.072、P = 0.002)。观察组患者中p53蛋白阳性者39例(39/90、43.33%),其中肿瘤大小≤ 2 cm者27例(27/39、69.23%)、TNM分期Ⅰ期、Ⅱ期、Ⅲ期和Ⅳ期分别占15.38%(6/39)、30.77%(12/39)、35.90%(14/39)和17.95%(7/39),淋巴结转移率为82.05%(32/39);p53蛋白阴性患者51例(51/90,56.67%),肿瘤大小≤ 2 cm者35例(35/51、68.63%)、TNM分期Ⅰ期、Ⅱ期、Ⅲ期和Ⅳ期分别占7.84%(4/51)、19.61%(10/51)、49.02%(25/51)和23.53%(12/51),淋巴结转移率为86.27%(44/51),p53蛋白阴性组与p53蛋白阳性组患者肿瘤大小、TNM分期及淋巴结转移率差异均无统计学意义(χ2 = 0.682、P = 0.462,χ2 = 0.491、P = 0.507,χ2 = 0.572、P = 0.461)。

结论

检测乳腺癌患者高危型人乳头状瘤病毒感染、p53蛋白表达及淋巴结转移率有助于对乳腺癌的诊疗;p53蛋白阳性率下降可能促进HPV感染相关肿瘤的发生和发展。

Objective

To investigate the high risk human papillomavirus (HPV) infection, p53 protein expression and lymph node metastasis among patients with breast cancer.

Methods

Total of 90 patients with breast cancer treated in Northwest Women and Children Hospital from May 2016 to May 2018 were selected as observation group and 90 patients with breast hyperplasia as control group. HPV genotype and p53 protein were detected in cancer tissues, while HPV genotype was detected in hyperplastic tissues. The high-risk HPV infection rate of all patients were detected. The tumor size, TNM stage, lymph node metastasis rate and p53 protein expression in patients with breast cancer were analyzed, respectively.

Results

There were 60 cases and 36 cases with high-risk HPV infection in observation group and control group, respectively. The infection rates of HPV16, 18 genotype in the observation group were 21.11% (19/90) and 22.22% (20/90), respectively, which were significantly higher than those of the control group [(2.22% (2/90) and 2.22% (2/90)], with significant differences (χ2 = 7.108, P = 0.001; χ2 = 8.063, P = 0.001). In the observation group, the lymph node metastasis rate of HPV positive patients was 93.33% (56/60), which was significantly higher than that of HPV negative patients (21/30, 70.00%), with significant difference (χ2 = 4.072, P = 0.002). Among the 90 cases with breast cancer, 39 cases were p53 protein positive, among whom, 27 cases (27/39, 69.23%) were with tumor size ≤ 2 cm, TNM stage Ⅰ, Ⅱ, Ⅲ and Ⅳ accounted for 15.38% (6/39), 30.77% (12/39), 35.90% (14/39) and 17.95% (6/39), respectively; the lymph node metastasis rate was 82.05% (32/39). There were 51 cases (56.67) with p53 protein negative among the observation group, 35 cases with tumor size ≤ 2 cm (35/51, 68.63%), and TNM stage Ⅰ, Ⅱ, Ⅲ and Ⅳ accounted for 7.84% (4/51), 19.61% (10/51), 49.02% (25/51) and 23.53% (12/51), respectively; the lymph node metastasis rate was 86.27% (44/51). There was no significant difference in tumor size, TNM stage and lymph node metastasis between the p53 protein positive group and p53 protein negative group (χ2 = 0.682, P = 0.462; χ2 = 0.491, P = 0.507; χ2 = 0.572, P = 0.461).

Conclusions

Detection of high risk HPV infection, p53 protein expression and lymph node metastasis rate of patients with breast cancer is helpful to the diagnosis and treatment, and the decrease of p53 protein positive rate may promote the occurrence and development of HPV infection related tumors.

表2 观察组与对照组高危型HPV感染基因型分布[例(%)]
表3 观察组HPV阴性和HPV阳性患者肿瘤大小、TNM分期以及淋巴结转移率[例(%)]
表4 观察组p53蛋白阴性和p53蛋白阳性患者肿瘤大小、TNM分期以及淋巴结转移率[例(%)]
表1 观察组和对照组患者的基本资料(± s
表5 p53蛋白阴性和p53蛋白阳性乳腺癌患者的HPV感染情况[例(%)]
[1]
郑文,郑建云,刘冰, 等. 乳腺癌组织中人乳头状瘤病毒与Rb, P53蛋白表达、预后的相关性分析[J]. 山西医科大学学报,2016,47(11):1026-1031.
[2]
刘现义,李中,王晓春, 等. 人乳头状瘤病毒感染与乳腺癌的关系及P16蛋白表达的相关性[J]. 中华医院感染学杂志,2016,26(9):2120-2122.
[3]
Ali SH, Al-Alwan NA, Al-Alwany SH. Detection and genotyping of human papillomavirus in breast cancer tissues from Iraqi patients[J]. E Mediterr Health J,2014,20(6):372-377.
[4]
Yang X, Lu L. Expression of HPV-16 E6 protein and p53 inactivation increases the uterine cervical cancer invasion[J]. Drug Research,2014,65(2):70-73.
[5]
刘现义,李中,王晓春, 等. 高危型人乳头状瘤病毒感染患者与乳腺癌的关系[J]. 中华医院感染学杂志,2016,26(2):393-394.
[6]
张雪云,王晓武,王丰梅. 乳腺癌组织中EZH2及p53蛋白表达及其临床意义[J]. 海南医学,2017,28(20):3303-3306.
[7]
侯红,方堃,陈耀坤, 等. 乳癌组织P53蛋白和Ki-67抗原表达及临床意义[J]. 齐鲁医学杂志,2017,6(4):401-403.
[8]
丁明剑,杨文华,白杨, 等. 乳腺癌患者外周血中TGF-β1和P53蛋白与临床特征的关系[J]. 河北医药,2017,39(10):1453-1456.
[9]
陶德友,朱文波. 乳腺癌组织中ZNF217和p53的表达及其临床意义[J]. 浙江医学,2017,39(17):1455-1457.
[10]
李黎洪,陈智伟,陈昱, 等. 三阴性乳腺癌组织中Stathmin, p53蛋白表达变化及意义[J]. 山东医药,2017,57(41):71-73.
[11]
谭敏华,雷伟华,胡志雄, 等. 乳腺癌组织中p53和Ki67蛋白的表达及意义[J]. 广东医学,2017,38(2):101-104.
[12]
罗仲燃,曾智豪,杨敏, 等. 佛山地区乳腺癌中ki67和p53蛋白表达的诊断价值[J]. 山西医药杂志,2018,13(15):254-258.
[13]
钱飚,鲁洪丰,励超, 等. 终末期乳腺癌患者高危型HPV感染与Stat3活性及IL-17表达意义研究[J]. 中华医院感染学杂志, 2017,27(23):5373-5376.
[14]
郝磊,魏现娟,郝坤. p53及bcl-2蛋白在乳腺癌中表达的相关性研究[J]. 中国妇幼保健,2017,32(4):695-697.
[15]
吕秀芳,宋晓霞,贺慧, 等. p16, p53及hTERC在人乳头状瘤病毒检测阴性子宫颈鳞状细胞癌中的表达[J]. 中华病理学杂志,2016,45(11):791-792.
[16]
Payandeh M, Sadeghi M, Sadeghi E, et al. Expression of p53 breast cancer in Kurdish women in the West of Iran: a reverse correlation with lymph node metastasis[J]. Asian Pac J Cancer P,2016,17(3):1261-1265.
[17]
闫石,霍明鸣,庞慧, 等. p53对绝经后HR阳性, HER-2阳性术后乳腺癌患者内分泌药物疗效的预测价值[J]. 实用肿瘤学杂志,2018,5(3):164-168.
[18]
Ngan C, Lawson JS, Clay R, et al. Early Human papilloma virus (HPV) oncogenic influences in breast cancer[J]. Breast Cancer,2015,9(9):93-97.
[19]
Bae JM, Kim EH. Human papillomavirus infection and risk of breast cancer: a meta-analysis of case-control studies[J]. Infect Agents Cancer,2016,11(1):14-18.
[20]
Mousavi T, Haghshenas M R, Rafiei A, et al. Hepatitis B virus genotypes distribution with HBsAg positive in the North of Iran (Mazandaran) during 2011-2014[J]. Arch Med Res Nlm, 2014,68(6):376-380.
[21]
王佩,孟桂芳. 乳腺癌HPV感染与P16蛋白失活的临床意义[J]. 中华医院感染学杂志,2013,23(13):3056-3058.
[22]
Fu L, Wang D, Shah W, et al. Association of human papillomavirus type 58 with breast cancer in shanxi province of China[J]. J Med Virol,2015,87(6):1034-1040.
[23]
王一,廖宏伟,宋扬. 三阴型乳腺癌患者血清VitD水平与瘤组织Ki-67, p53蛋白表达变化及其相关性[J]. 山东医药,2018,9(11):207-212.
[24]
Tortora M, Annunziata C, Liguori G, et al. Detection of human papillomavirus DNA in peri-tumor tissues and pelvic lymph nodes as potential molecular marker of micrometastasis in cervical cancer[J]. Infect Agents Cancer,2016,11(1):22-25.
[25]
江飞云,吴名彩,倪观太. 乳腺癌患者BRCA基因突变检测及P53蛋白表达分析[J]. 中国病原生物学杂志,2017,3(1):79-82.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[2] 刘伟, 牛云峰, 安杰. LINC01232 通过miR-516a-5p/BCL9 轴促进三阴性乳腺癌的恶性进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 330-338.
[3] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[4] 韩婧, 郝少龙, 康骅. 北京市单中心甲状腺癌患者临床特征的回顾分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 490-493.
[5] 张钊, 骆成玉, 张树琦, 何平, 李旭斌. 不同术式治疗早期乳腺癌的效果及并发症发生率、复发率比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 494-497.
[6] 宋佳, 汪波, 孙凯律, 商江峰, 吴旦平, 肇毅. 吲哚菁绿荧光显影联合亚甲蓝染色在乳腺癌前哨淋巴结活检中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 498-501.
[7] 孙建娜, 孔令军, 任崇禧, 穆坤, 王晓蕊. 266例首诊Ⅳ期乳腺癌手术患者预后分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 502-505.
[8] 唐丹萍, 王萍, 江孟蝶, 杨晓蓉. 自体脂肪移植在乳腺癌术后乳房重建的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 582-585.
[9] 陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[10] 刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[11] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[12] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[13] 王帅, 张志远, 苏雨晴, 李雯雯, 王守凯, 刘琦, 李文涛. 孟德尔随机化及其在乳腺癌研究中的应用进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 671-676.
[14] 王曦娅, 尹弘青, 丁伟, 徐滨, 于海源, 马东升, 邵军. 桥本背景下甲状腺乳头状癌多参数分析预测大容量淋巴结转移[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 548-554.
[15] 张梦婷, 穷拉姆, 色珍, 李逸群, 德庆旺姆. 西藏地区藏族乳腺癌新辅助化疗的真实世界研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 441-446.
阅读次数
全文


摘要